No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Researchers found that higher ocrelizumab exposure over 10 years was associated with less risk of disability progression in ...

A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple sclerosis (MS) failed to meet its primary endpoint. The study aimed to determine whether treatment with ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis The trial ...

WEST PALM BEACH, Fla. — Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, findings confirmed by data from a series of ...

Each year, the Breakthrough Prize, sometimes dubbed the “Oscars of Science”, honors scientists whose discoveries push the boundaries of human knowledge and change lives. Yes, including sclerosis this ...

Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and ...